Displaying 2221 - 2240 of 4420
Steris/Synergy Health, In the Matter of
The FTC issued an administrative complaint charging that Steris Corporation’s proposed $1.9 billion acquisition of Synergy Health plc would violate the antitrust laws by significantly reducing future competition in regional markets for sterilization of products using radiation, particularly gamma or x-ray radiation. The Commission also authorized agency staff to seek a temporary restraining order and preliminary injunction in federal court to maintain the status quo pending an administrative trial on the merits. According to the FTC, it is unlikely that new competitors in the market for contract radiation sterilization services would replicate the competition that would be eliminated by the merger. The Commission alleged that the challenged acquisition would eliminate likely future competition between Steris’s gamma sterilization facilities and Synergy’s planned x-ray sterilization facilities in the United States, thus depriving customers of an alternative sterilization service and additional competition. On September 25, 2015 the district court denied the FTC motion for a PI. On October 30, the Commission dismissed the administrative complaint.
Investor Len Blavatnik to Pay $656,000 to Settle FTC Charges That He Violated U.S. Premerger Notification Requirements
1509006 Informal Interpretation
FTC Files Amicus Brief Explaining that Pharmaceutical “Product Hopping” Can Violate the Antitrust Laws
National Association of Animal Breeders, Inc., In the Matter of
The National Association of Animal Breeders (NAAB) agreed to remove provisions in its Code of Ethics that the FTC charged limit competition among its members. The consent order settling the FTC’s allegations requires NAAB to end certain advertising restrictions, remove references to the restrictions from its website and official documents, publish and distribute an announcement regarding the consent agreement and the resulting changes to the Code of Ethics, and implement an antitrust compliance program.
1509005 Informal Interpretation
Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al.
FTC Requires Divestitures Prior to Merger of Orthopedic Device Companies
1509004 Informal Interpretation
1509003 Informal Interpretation
1509002 Informal Interpretation
FTC Approves Application for Modification of Divestiture Agreement Between Albertsons and Haggen Holdings, LLC
FTC Requires Divestitures in Connection with Endo International plc’s Proposed Acquisition of Par Pharmaceuticals, Inc.
Displaying 2221 - 2240 of 4420